Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 812-815

  Kröger, Nicolaus ^a   Zabelina, Tatjana ^a   Alchalby, Haefaa ^a   Stübig, Thomas ^a   Wolschke, Christine ^a   Ayuk, Francis ^a   von Hünerbein, Natascha ^a   Kvasnicka, Hans Michael ^b   Thiele, Jürgen ^c   Kreipe, Hans Heinrich ^d   Büsche, Guntram ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Allogeneic stem cell transplantation; Bone marrow fibrosis; Fibrosis regression; JAK2 mutation; Myelofibrosis

Indexed keywords

BUSULFAN; FLUDARABINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHIMERA; ERYTHROCYTE TRANSFUSION; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; OVERALL SURVIVAL; POLYCYTHEMIA VERA; REDUCED INTENSITY CONDITIONING; REMISSION; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTHEMIA; ADOLESCENT; ALLOTRANSPLANTATION; BONE MARROW; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PATHOLOGY; PRIMARY MYELOFIBROSIS; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE MARROW; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84899943540     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.019     Document Type: Article

References (25)

1. Tefferi A., Constantinescu S.N. Introduction to "A special spotlight review series on BCR-ABL-negative myeloproliferative neoplasms.". Leukemia 2008, 22:3-13.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342:1255-1266.
3. Chagraoui H., Komura E., Tulliez M., et al. Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100:3495-3503.
4. Le Bousse-Kerdilès M.C., Martyré M.C., Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 2008, 19:69-80.
5. Thiele J., Kvasnicka H.M. Grade of bone marrow fibrosis is associated with relevant hematological findings: a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 2006, 85:226-232.
6. Barosi G., Rosti V., Bonetti E., et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. Plos ONE 2012, 7:e35631.
7. Gianelli U., Vener C., Bossi A., et al. The European consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2013, 25:1193-1202.
8. Nazha A., Estrov Z., Cortes J., et al. Prognostic implications and clinical characteristics associated with bone marrow fibrosis. Leuk Lymphoma 2013, 54:2537-2539.
9. Strasser-Weippl K., Steurer M., Kees M., et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 2006, 47:441-450.
10. Anger B., Seidler R., Haug U., et al. Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica 1990, 75:226-234.
11. Alchalby H., Yunus D.-R., Zabelina T., et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012, 157:75-85.
12. Cervantes F., Barosi G., Demory J.L., et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998, 102:684-690.
13. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
14. Gangat N., Caramazza D., Vaidya R., et al. DIPSS Plus: a refined Dynamic International Porgnostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29:392-397.
15. Passamonti F., Cervantes F., Vannucchi A.M., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
16. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
17. Thiele J., Kvasnicka H.M., Dietrich H., et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005, 20:879-889.
18. Silver R.T., Vadris K., Goldman J.J. Recombinant Interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011, 117:6669-6672.
19. Tefferi A., Verstovsek S., Barosi G., et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009, 27:4563-4569.
20. Kvasnicka H.M., Thiele J., Bueso-Ramos C.E., et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol 2013, 31(Suppl). abstract 7030.
21. Thiele J., Kvasnicka H.M., Facchetti F., et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematology 2005, 90:1128-1133.
22. Kröger N., Badbaran A., Holler E., et al. Monitoring of the JAK2V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321.
23. Kröger N., Holler E., Kobbe G., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:5264-5270.
24. Kröger N., Thiele J., Zander A., et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007, 35:1719-1722. MDS Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
25. Kerbauy D.M., Gooley T.A., Sale G.E., et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007, 13:355-365.